Trials / Not Yet Recruiting
Not Yet RecruitingNCT07387003
Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes
A Multicenter Phase 2 Clinical Study to Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Oral Antidiabetic Drugs or Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 345 (estimated)
- Sponsor
- Gan & Lee Pharmaceuticals. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GZR101-80 | Administered SC |
| DRUG | GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30) | Administered SC |
Timeline
- Start date
- 2026-04-10
- Primary completion
- 2027-02-11
- Completion
- 2027-09-23
- First posted
- 2026-02-04
- Last updated
- 2026-04-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07387003. Inclusion in this directory is not an endorsement.